Key clinical point: Nonalcoholic fatty liver disease (
Major finding: Advanced fibrosis occurred in 4.5% of lean patients with NAFLD, compared with 2.3% of obese patients.
Study details: A large population-based cohort study conducted in the general population in France.
Disclosures: The investigators disclosed relationships with Gilead, AbbVie, Echosens, and others.
Serfaty L et al. The Liver Meeting 2019,.